NUZ -- New Investor thread, page-369

My take - whilst MT might have set the tone, it was all new news. At some point the stats and promotion of the Ph1 trial comes to an end. Now the market wants to see progress, but NUZ is hampered by Healy constraints currently. Nonetheless, the company continues to move forward with preclinical work and promotion. What else do shareholders want them to do? They can't hurry up Ph2 and they can't make pre-clinical results just appear. So how else can they drive NUZ forward? Seems to me the only option is continued promotion through interviews and conferences - which MT is doing tirelessly.

I think the SP reflected the excitement of the Ph1, which slowly tapered off with the realization that it is still going to be a bit of a wait, and obviously we took a hit with the Board change and shenanigans going on there.

Yes, NUZ have more staff than ever, because they have been setting up the infrastructure that will lead to our success. We needed to commence the pre-clinicals, and so that work in progress adds costs and time.

I disagree that MT has dropped investor interaction. He is still answering questions on the Investor Page (yes, there are some old ones not answered), and he is still releasing information as it becomes available.

Of course you're entitled to your rant, and of course shareholders are disappointed we haven't returned to the higher prices first set when the Ph1 and initial OLE results came out, but there is news on the way (European ODD, OLE study update, IND update, Healy commencement, etc), albeit out of NUZ's control to speed any of it up!